Nuvalent, Inc.

NASDAQ:NUVL

Biotechnology

Healthcare
$123.96 -0.02%

-$0.03 today

Market cap
$9.13B
Beta
1.15
P/E (TTM)
-21.6
EPS (TTM)
-$5.72
52W Low $71.13High $123.62

Volume 0.00M

Average 1.91M

NUVL Income Tax Expense

Income taxes recognized for the period, including current and deferred tax.

Nuvalent, Inc.NASDAQ: NUVL

Income Tax Expense · Q1 FY2026 · quarter ended Mar 2026

Income tax expense grows, but more slowly than its trailing trend

Q1 FY2026 income tax expense of $168K rose 7.0% year over year, behind the +10.8% change in trailing-twelve-month income tax expense. Sequentially, it rose 11.3% from the prior quarter.

Context

  • Income tax expense increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +7.0% toward the trailing-twelve-month pace of +10.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$168K+11.3% QoQ
Last fiscal yearDec 2025
$585K-23.4% YoY
LTMMar 2026
$596K+10.8% YoY
Income Tax Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+7.0%——
1 year-23.4%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Tax Expense history

USD · from the income statement

Latest · FY2025
585K USD
Year-over-year change
-23.4%

Income Tax Expense vs competitors

How NUVL compares with its peers on the latest reported figures

  • Peers report in different currencies, so income tax expense is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +10.8% is the 4th highest of 6, against a peer median of +116.0%.
NUVL Competitors
Income Tax Expense for NUVL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
JAZZJazz Pharmaceuticals plcLTM Sep 2026$53.58M USD+116.0%—1.1%
ABVXAbivax S.A.FY2025€5.85M EUR———
CRSPCRISPR Therapeutics AGLTM Sep 2026$2.34M USD-37.1%—9.3%
RYTMRhythm Pharmaceuticals, Inc.LTM Sep 2026$1.57M USD+258.0%—0.6%
NUVLNuvalent, Inc.LTM Mar 2026$596K USD+10.8%——
AXSMAxsome Therapeutics, Inc.LTM Jun 2026$558K USD+163.8%—0.1%
CYTKCytokinetics, IncorporatedLTM Jun 2026$0 USD——0.0%
PCVXVaxcyte, Inc.LTM Jun 2026$0 USD———
ARWRArrowhead Pharmaceuticals, Inc.LTM Sep 2026-$6.78M USD-131.7%—1.5%
Peer median (excluding NUVL) —+116.0%—0.8%

Competitors are the stored peer set for NUVL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development35.56M63.73M113.24M217.77M306.97M
Selling, General & Admin10.26M22.38M36.25M62.59M107.34M
Operating Expenses45.82M86.11M149.49M280.37M414.31M
Depreciation & Amortization215K00280.37M414.31M
EBITDA(46.12M)(81.85M)(126.22M)20.38M(10.49M)
EBITDA Margin—————
Operating Income(45.82M)(86.11M)(149.49M)(280.37M)(414.31M)
Operating Margin—————
Interest Income0023.27M38.32M44.74M
Interest Expense0023.27M00
Other Income / Expenses(521K)4.25M23.27M20.38M(10.49M)
Income Before Tax(46.34M)(81.85M)(126.22M)(259.99M)(424.79M)
Pre-Tax Margin—————
Income Tax Expense000764K585K
Net Income(46.34M)(81.85M)(126.22M)(260.76M)(425.38M)
Net Margin—————
EPS (Basic)(2.13)(1.65)(2.17)(3.93)(5.85)
EPS (Diluted)(2.13)(1.65)(2.17)(3.93)(5.85)
Weighted Avg Shares21.78M49.67M58.22M66.41M72.69M
Weighted Avg Shares (Diluted)21.78M49.67M58.22M66.41M72.69M

Nuvalent, Inc.

NASDAQ:NUVL

Intrinsic Alpha fair value

Locked

Current Price

$123.96

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.